The addition of a programmed death ligand 1 inhibitor to standard chemotherapy as first-line treatment of patients with advanced non-small-cell lung cancer results in significantly longer overall survival and progression-free survival.

Research in Review

A study of SMARCA/BRG1 expression in patients with non-small cell lung (NSCLC) cancer has found that it is a significant indicator of prognosis and a novel predictive biomarker for increased sensitivity to platinum-based chemotherapy.

Read More

Early results of a head-to-head trial comparing two prominent treatments for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) could have a significant impact on clinical decision making for this patient population.

Read More

A newly developed “liquid biopsy” assay that detects free-floating DNA from cells in blood plasma may be an effective tool for detecting mutations in patients with non-small cell lung cancer (NSCLC), according to the results from a recent study.

Read More

Subscribe to Non-Small Cell Lung Cancer